June 24, 2022 News Cytiva is opening a new, larger facility on its Uppsala site to expand its manufacturing capacity of the Sephadex and Cytodex product families. You Might Also Like Codex DNA Releases Full-Length Synthetic Genome for Highly Infectious SARS-CoV-2 Delta Variant September 3, 2021 Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests July 28, 2021 Mission Bio’s New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products April 26, 2024
Codex DNA Releases Full-Length Synthetic Genome for Highly Infectious SARS-CoV-2 Delta Variant September 3, 2021
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests July 28, 2021
Mission Bio’s New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products April 26, 2024